Tristel, the Suffolk based supplier of infection and contamination control products, announced a number of regulatory approvals over the past week including a licence for its Stella system in China and approvals for its Wipes system in Australia and Hong Kong. An increase in overseas sales is a key part of their growth strategy.

The anticipated licence necessary for selling the Stella instrument disinfectant tray system in China has been granted. In April, Tristel attributed shortfalls in market expectations to regulatory delays in China and Germany. In related news, a recent clinical study (due to be published later this year) found the Stella system to be equivalent in endoscope cleaning efficacy and realised significant savings in system costs and prossessing time when compared with the world's leading brand of instrument disinfectant used in combination with a popular endoscope washer.

Tristel's chlorine dioxide-based wipes for small flexible endoscopes have received regulatory approval from the Therapeutic Goods Association (TGA), the body that regulates disinfectant use in Australia, and from the Disinfectant & Sterliant Assessment Committee (DSAC) in Hong Kong.

[Note: The Wipes System has not yet been included in Germany's Verbund fur Angewandte Hygiene (VAH) listing - a pre-condition for selling into the country's public hospital system.]

Tristel also reported that a new distributor has been appointed in New Zealand. Tristel currently supplies to over half of the 35 private hospitals in New Zealand and the new distributor Tytex Ltd will target sales at public hospitals. In related regional news, a distributor for the much larger Australian healthcare market is expected to be appointed shortly.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here